EMBI - Emerald Bioscience's formulated THC prodrug effective at reducing IOP animal study shows

Emerald Bioscience ([[EMBI]] -0.3%) has announced that its THC prodrug, THCVHS, optimized through a nanoemulsion formulation (THCVHS-NE) in animal models, demonstrated significantly better reduction of intraocular pressure ((IOP)) compared to the commercially approved standard of care. The company plans to initiate human study in Q3 of 2021.THCVHS-NE achieved a maximum drop in intraocular pressure  of 23% compared to latanoprost (13%) and timolol (14%). In addition, duration of response for THCVHS-NE was ?480 minutes, compared to latanoprost (?360 minutes) and timolol (?90 minutes).

For further details see:

Emerald Bioscience's formulated THC prodrug effective at reducing IOP, animal study shows